RecruitingNot ApplicableNCT05783505

A Multicomponent Intervention Program to Prevent and Reduce ICU Agitation and Physical Restraint Use

PRevention of pAtient's agItation and Enhancement of Their SafEty (PRAISE): Improving Intensive Care Treatment Using a Multicomponent Pharmacological Intervention


Sponsor

Radboud University Medical Center

Enrollment

480 participants

Start Date

Jun 1, 2023

Study Type

INTERVENTIONAL

Conditions

Summary

Despite deleterious effects, physical restraints are still commonly used in (expected to become) agitated patients in Dutch ICUs (20-25%). This study aims to determine the effectiveness of a person-centered multicomponent intervention (MCI) program consisting of non-pharmacological interventions combined with goal directed light sedation using dexmedetomidine compared to the old standard of care including physical restraints in (expected to become) agitated adult ICU patients.


Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying Multicomponent intervention program for people with agitation,psychomotor. The study is currently recruiting participants at 5 locations. People eligible for this study include aged 18 Years and older.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

OTHERMulticomponent intervention program

Non-pharmacological interventions combined with goal directed sedation using dexmedetomidine if needed


Locations(5)

Noordwest Ziekenhuisgroep

Alkmaar, Netherlands

Bravis Ziekenhuis

Bergen op Zoom, Netherlands

Amphia Ziekenhuis

Breda, Netherlands

Elkerliek Ziekenhuis

Helmond, Netherlands

VieCuri Medisch Centrum

Venlo, Netherlands

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT05783505


Related Trials